TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26625989
Drug: Multimodal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal analgesia regime comprising systemic anti‐inflammatory agents and opioids
Study: 23263241
Drug: Nebivolol 5
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 5 mg/day
Study: 19134126
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 5% SAP and 0.2% retinol
Study: 16786230
Drug: Extended-duration thromboprophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-duration thromboprophylaxis with enoxaparin 40 mg subcutaneously once daily for an additional 28 +/- 4 days
Study: 16786230
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen of enoxaparin 40 mg subcutaneously once daily for 10 +/- 4 days
Study: 11389491
Drug: Cefoperazone-sulbactam plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone-sulbactam plus cotrimoxazole (cefoperazone 25 mg/kg/day, TMP-SMZ at a ratio of 80:400, TMP 8 mg/kg/day)
Study: 11389491
Drug: Ceftazidime plus
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime plus cotrimoxazole (ceftazidime 100 mg/kg/day, TMP-SMZ at a ratio of 80:400, TMP 8 mg/kg/day)
Study: 8978577
Drug: UFT (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (350 mg/m2/day orally x 14 days)
Study: 8978577
Drug: 5-FU (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU (500 mg/m2 I.V. days 1 and 8)
Study: 24519752
Drug: Intravenous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous trastuzumab plus chemotherapy
Study: 22360924
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone plus orally administered 17 Beta estradiol
Study: 24215741
Drug: Sandwich bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandwich bone augmentation (SBA) technique
Study: 24215741
Drug: Sandwich bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandwich bone augmentation (SBA) technique with critical crest angulation (CA) < 150°
Study: 24215741
Drug: Sandwich bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandwich bone augmentation (SBA) technique with critical crest angulation (CA) > 150°
Study: 23461841
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg glucophage po bid for 12 weeks
Study: 23461841
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg magnesium oxide po bid for 12 weeks
Study: 23461841
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg spironolactone po bid for 12 weeks
Study: 15230484
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg AT-1015 BID
Study: 15230484
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg AT-1015 BID
Study: 15230484
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg AT-1015 BID
Study: 9386849
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment (n = 21)
Study: 9386849
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) (n = 8)
Study: 7970064
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (parnaparin)
Study: 3299090
Drug: Oral azidothymidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral azidothymidine (AZT)
Study: 29746726
Drug: Generic candesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic candesartan 16 mg
Study: 29746726
Drug: Branded formulation
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded formulation
Study: 27585757
Drug: Early invasive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early invasive treatment strategy (aiming for revascularisation within 7 days)
Study: 17604045
Drug: Early invasive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early invasive treatment strategy
Study: 20802322
Drug: Hydroxyethyl starch
Normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starch (10% solution of pentastarch)
Study: 18187744
Drug: Sildenafil (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (20, 40, or 80 mg three times daily)
Study: 8352673
Drug: Nicardipine hydrochloride
Normalized name: Nicardipine Hydrochloride
DrugBank: Nicardipine (DB00622)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicardipine hydrochloride (20 mg)
Study: 8352673
Drug: Clonidine hydrochloride
Normalized name: Clonidine Hydrochloride
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine hydrochloride (0.1 mg)
Study: 8352673
Drug: Drug-treated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-treated group (overall)
Study: 3602599
Drug: Ambroxol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol (30 mg tablet 3 times/day for adults; 9 mg syrup 4 times/day for children)
Study: 31272404
Drug: Parent-led strategies
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-led strategies informed by behavioral economics implemented in 6 weekly cooking skills classes
Study: 28836285
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene instruction (OHI), scaling and root debridement (n = 11)
Study: 21136011
Drug: edoxaban 30
Normalized name: edoxaban 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: edoxaban 30 mg qd
Study: 21136011
Drug: edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: edoxaban 60 mg qd
Study: 21136011
Drug: warfarin (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: warfarin (dose adjusted to INR of 2-3)
Study: 3206202
Drug: Chlorhexidine gel
Normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gel (1% digluconate) applied in a custom tray for the mandibular arch, 10 min daily for 14 days with oral hygiene measures (toothbrush, toothpaste, dental floss)
Study: 3206202
Drug: Chlorhexidine gel
Normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gel (1% digluconate) applied in a custom tray for the mandibular arch, 10 min daily for 14 days without oral hygiene measures
Study: 15723742
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplements (237 mL/d of 4 or 8 kJ/mL) for 4 weeks
Study: 11110008
Drug: Citalopram (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (active drug)
Study: 2005733
Drug: 84 g
Normalized name: ZINC OXIDE 9.84 g in 50 mL TOPICAL LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 84 g of oatmeal
Study: 2005733
Drug: 56 g
Normalized name: PETROLATUM 30.8 g in 56 g TOPICAL OINTMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 56 g of oat bran
Study: 2005733
Drug: 84 g
Normalized name: ZINC OXIDE 9.84 g in 50 mL TOPICAL LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 84 g of oat bran
Study: 2005733
Drug: 56 g
Normalized name: PETROLATUM 30.8 g in 56 g TOPICAL OINTMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 56 g of oatmeal
Study: 2005733
Drug: 28 g
Normalized name: SM Syringe 28 g, 0.5cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 g of farina (beta-glucan control)
Study: 6824299
Drug: Subcutaneous bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous bupivacaine injection around the wound
Study: 28238190
Drug: Resveratrol 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 500 mg/day
Study: 28238190
Drug: Resveratrol 40
Normalized name: RESVERATROL 400 mg / NICOTINAMIDE MONONUCLEOTIDE 500 mg / WHITE PEPPER 50 mg ORAL LOZENGE [Ascuoli]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 40 mg/day
Study: 20534325
Drug: L-carnitine-supplemented (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine-supplemented (10 mg/[kg d])
Study: 15863374
Drug: Quadrivalent HPV
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV vaccine (20 microg type 6, 40 microg type 11, 40 microg type 16, and 20 microg type 18) administered at day 1, month 2, and month 6.
Study: 15863374
Drug: Placebo preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo preparations (two types).
Study: 12787419
Drug: Flow group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flow group (Qa <600 mL/min or clinical criteria)
Study: 8717471
Drug: Casodex (bicalutamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casodex (bicalutamide, 50 mg once daily) plus LHRH analogue (Zoladex 3.6 mg every 28 days or leuprolide 7.5 mg every 28 days)
Study: 8717471
Drug: Flutamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (250 mg three times daily) plus LHRH analogue (Zoladex 3.6 mg every 28 days or leuprolide 7.5 mg every 28 days)
Study: 8717471
Drug: Casodex (bicalutamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casodex (bicalutamide, 50 mg once daily) plus LHRH analogue
Study: 8717471
Drug: Flutamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (250 mg three times daily) plus LHRH analogue
Study: 1648598
Drug: Cyclic-alternating treatment
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic-alternating treatment with ifosfamide/etoposide (IE), cyclophosphamide, doxorubicin, and vincristine (CAV)
Study: 1648598
Drug: Response-oriented treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Response-oriented treatment with IE therapy up to maximal response and subsequently an immediate switch to CAV
Study: 1648598
Drug: Limited-stage disease
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limited-stage disease (LD) patients with cyclic-alternating treatment
Study: 1648598
Drug: Limited-stage disease
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limited-stage disease (LD) patients with response-oriented treatment
Study: 1648598
Drug: Extensive-stage disease
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extensive-stage disease (ED) patients with cyclic-alternating treatment
Study: 1648598
Drug: Extensive-stage disease
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extensive-stage disease (ED) patients with response-oriented treatment
Study: 30129806
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Nigella sativa and Vitex agnus-castus with citalopram
Study: 28155305
Drug: Training programme
Normalized name: PUMP,LUTREPULSE PROGRAMMABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training programme for Tanzanian caregiver students in relational communication therapy (RCT)
Study: 17449836
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of medication and contingencies
Study: 17449836
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of medication and reward
Study: 17449836
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of medication and response cost
Study: 15057257
Drug: Sildenafil 100
Normalized name: sildenafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 100 mg before intercourse
Study: 16459225
Drug: TAG meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAG meal (10 g of TAG oil)
Study: 10802151
Drug: Enalapril, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril, 10 mg/day
Study: 10802151
Drug: Nifedipine, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine, 30 mg/day
Study: 1353368
Drug: bisoprolol 10
Normalized name: bisoprolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: bisoprolol 10 mg daily
Study: 1353368
Drug: diazepam 5
Normalized name: diazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam 5 mg twice daily
Study: 6143631
Drug: ICI 118551
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 118551 (beta 2 antagonist)
Study: 24559858
Drug: Botox injection
Normalized name: Botox
DrugBank: DaxibotulinumtoxinA (DB17929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botox injection at the bladder neck (100 IU)
Study: 24559858
Drug: Standard conservative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard conservative treatment (both groups)
Study: 20620037
Drug: Tiotropium 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 5 microg via Respimat inhaler once daily for 48 weeks
Study: 20620037
Drug: Placebo via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo via Respimat inhaler once daily for 48 weeks
Study: 17289892
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg, twice daily starting on day 2 of cycle 1)
Study: 17289892
Drug: Irinotecan (escalated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (escalated doses of 180, 200, 220, and 260 mg/m2 in FOLFIRI regimen)
Study: 15855216
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation at 400 mg/day for 9 months
Study: 11939671
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined hormone replacement therapy (Kliogest)
Study: 9571328
Drug: High-salt diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-salt diet (255 mEq of sodium daily)
Study: 9571328
Drug: Low-salt diet
Normalized name: Low-energy diets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-salt diet (85 mEq of sodium daily)
Study: 7542021
Drug: Primary chemotherapy
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary chemotherapy in addition to best supportive care
Study: 25352095
Drug: Control (untreated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (untreated patches)
Study: 18518863
Drug: Galantamine (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (long-term treatment > 6 months)
Study: 18518863
Drug: Galantamine (short-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (short-term treatment ≤ 6 months)
Study: 16269184
Drug: pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pegylated interferon α-2b (1.5 μg/kg once weekly) plus ribavirin (800 mg daily) for 48 weeks for HCV genotypes 1/4 and 24 weeks for genotypes 2/3
Study: 29306047
Drug: Cognitive-behavioral strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral strategy for discontinuing long-term serotonin reuptake inhibitors (SRIs)
Study: 24642779
Drug: Dairy dessert
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dairy dessert containing maltitol and scFOS (35g dosage)
Study: 16012278
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg/d) + Cognitive Behavioral Therapy (12 sessions)
Study: 16012278
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg/d) + Motivational Enhancement Therapy (4 sessions)
Study: 16012278
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Cognitive Behavioral Therapy (12 sessions)
Study: 16012278
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Motivational Enhancement Therapy (4 sessions)
Study: 14964345
Drug: Lacteol group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacteol group (2 capsules of Lacteol Fort twice a day for 4 weeks)
Study: 14964345
Drug: Lacidophilin group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidophilin group (5 chewable tablets of Lacidophilin three times a day for 4 weeks)
Study: 8759812
Drug: zofenopril (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: zofenopril (7.5 to 30 mg twice daily)
Study: 7065839
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of dextroamphetamine (intravenous)
Study: 7065839
Drug: Double-blind pimozide
Normalized name: Pimozide
DrugBank: Pimozide (DB01100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double-blind pimozide treatment
Study: 31358046
Drug: Micro-fragmented adipose
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-fragmented adipose tissue injection (Lipogems®)
Study: 27176822
Drug: Tdap vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap vaccine during pregnancy
Study: 12006327
Drug: Ibandronate 2.5
Normalized name: ibandronate 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 2.5 mg daily
Study: 15197541
Drug: Ibandronate 20
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 20 mg intermittently
Study: 15197541
Drug: Ibandronate 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 1.0 mg IV every 3 months
Study: 15197541
Drug: Ibandronate 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 0.5 mg IV every 3 months
Study: 9841833
Drug: Ia-TT conjugate
Normalized name: magnesium aluminum silicate type Ia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ia-TT conjugate (dose range, 3.75-63 microg of CPS component)
Study: 9841833
Drug: Ib-TT conjugate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ib-TT conjugate (dose range, 3.75-63 microg of CPS component)
Study: 2508417
Drug: Triphasic oral
Normalized name: CeeNU, triphasic oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic oral contraceptive containing ethinylestradiol and levonorgestrel
Study: 8749599
Drug: Triphasic oral
Normalized name: CeeNU, triphasic oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic oral contraceptive containing ethinylestradiol and desogestrel
Study: 6124805
Drug: Early phototherapy
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early phototherapy started at serum bilirubin 250 mumol/l
Study: 6124805
Drug: Late phototherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late phototherapy started at serum bilirubin 320 mumol/l
Study: 29736552
Drug: Anodal tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anodal tDCS over the left inferior frontal gyrus (l-IFG)
Study: 29736552
Drug: Anodal tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anodal tDCS over the left posterior superior temporal gyrus (l-STG)
Study: 20578849
Drug: Immediate orthodontic
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate orthodontic loading (11 implants)
Study: 20578849
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (9 implants)
Study: 3082677
Drug: Topical nitroglycerin
Normalized name: nitroglycerin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nitroglycerin vasodilator cream
Study: 29314645
Drug: Placebo→tofacitinib 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo→tofacitinib 5 mg twice daily
Study: 29314645
Drug: Placebo→tofacitinib 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo→tofacitinib 10 mg twice daily
Study: 16612399
Drug: Vasodilators and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasodilators and diuretics
Study: 23792149
Drug: Adalimumab (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (80 mg loading dose followed by 40 mg every 2 weeks)
Study: 20629134
Drug: Exercise program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise program (6-month minimally supervised); attended a monthly exercise class and exercised at home three times weekly
Study: 16093518
Drug: Perceived treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived treatment severity and life threat
Study: 8777336
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg b.i.d. for 3 months)
Study: 8777336
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg b.i.d. for 6 months)
Study: 29249596
Drug: Telephone counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone counseling by pharmacist bi-monthly for one year
Study: 17490976
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and riboflavin supplementation (30 mg Fe and 6 mg riboflavin) with vitamin A-fortified rice
Study: 12925454
Drug: Pexelizumab 2.0‐mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pexelizumab 2.0‐mg/kg bolus
Study: 12925454
Drug: Pexelizumab 2.0‐mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pexelizumab 2.0‐mg/kg bolus and 0.05‐mg/kg per h infusion for 20 hours
Study: 9122580
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy (uvulopalatopharyngoplasty (UPPP), nasal surgery, maxillofacial surgery)
Study: 1513833
Drug: Foamed gel
Normalized name: Rectal Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foamed gel dressing
Study: 6186852
Drug: Once-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing of acebutolol
Study: 6186852
Drug: Twice-a-day dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-a-day dosing of acebutolol
Study: 31724343
Drug: Formulation AH
Normalized name: phenylephrine hydrochloride Chewable Tablet [Ah-Chew D]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation AH
Study: 31724343
Drug: Formulation AK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation AK
Study: 31724343
Drug: Reference (single-entity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference (single-entity tablets)